仕佳光子(688313.SH):目前聚焦於電信領域和數據中心領域的DFB、EML等相關產品正在努力開發中
格隆匯5月24日丨仕佳光子(688313.SH)於2023年5月22日10:00-11:00接受機構調研,問答環節中,就“未來DFB激光器的規劃如何?”,公司回覆稱,公司於2016年啟動有源產品的研發,“無源+有源”的光電集成模式是我們公司未來的發展方向和目標。目前聚焦於電信領域和數據中心領域的DFB、EML等相關產品正在努力開發中;同時,在硅光用大功率激光器芯片、激光雷達用光源芯片、半導體光放大器等方面也取得顯著突破。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.